# PLRX — Pliant Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** PLRX  
**Sources:** 8  
**Published:** 2026-10-26  
**Canonical:** https://app.k3vl4r.com/research/deep-research-plrx-pliant-therapeutics-inc-catalysts-narrative-risks-9446

---

# Pliant Therapeutics, Inc. (PLRX) — Research Snapshot

*As of 2026-10-26. This is a summary of available information, not investment advice.*

## Recent Catalysts (last ~1–3 months)

**Q2 2026 earnings and corporate update (Aug. 11, 2026)** — Pliant reported second-quarter results and provided a portfolio update. Highlights included FORTIFY (Phase 1b indication expansion of PLN-101095) "experiencing strong enrollment, progressing ahead of schedule," and the appointment of two seasoned oncology drug-development leaders—Flavia Borellini, Ph.D., and Robert Iannone, M.D., M.S.C.E.—to the board. R&D expenses fell to $16.7M (from $32.2M year-ago), G&A to $7.1M (from $13.4M), and net loss narrowed to $22.4M (from $43.3M). As of June 30, 2026, the company reported cash, cash equivalents and short-term investments of $159.6 million. [[3]](https://finance.yahoo.com/healthcare/articles/pliant-therapeutics-provides-corporate-reports-200500096.html), [[10]](https://markets.financialcontent.com/gatehouse.rrstar/article/gnwcq-2026-8-11-pliant-therapeutics-provides-corporate-update-and-reports-second-quarter-2026-financial-results)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-plrx-pliant-therapeutics-inc-catalysts-narrative-risks-9446 (free to sign up)._